Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Myeloid 1Lymphoid 1Classical hematology 1

Conditions

Leukemia, Myeloid, Acute 229Leukemia, Lymphocytic, Chronic, B-Cell 213Leukemia 203Myelodysplastic Syndromes 185Precursor Cell Lymphoblastic Leukemia-Lymphoma 174Lymphoma 148Lymphoma, Non-Hodgkin 142Multiple Myeloma 131Hodgkin Disease 123Lymphoma, Follicular 111Lymphoma, Mantle-Cell 108Lymphoma, Large B-Cell, Diffuse 96Lymphoma, B-Cell, Marginal Zone 89Myeloproliferative Disorders 86Congenital Abnormalities 85Burkitt Lymphoma 85Leukemia, Myelomonocytic, Chronic 77Leukemia, Myelogenous, Chronic, BCR-ABL Positive 75Leukemia, Myeloid, Chronic-Phase 74Leukemia, Myeloid, Accelerated Phase 73Recurrence 63Melanoma 62Lymphoma, Large-Cell, Immunoblastic 61Anemia, Refractory, with Excess of Blasts 60Neoplasms, Plasma Cell 56Waldenstrom Macroglobulinemia 55Primary Myelofibrosis 55Blast Crisis 55Hematologic Neoplasms 45Lymphoma, T-Cell, Cutaneous 42

Interventions

Cyclophosphamide 3thymoglobulin 2luspatercept 2fludarabine 2Rituximab 2Melphalan 2Busulfan 2fludarabine phosphate 1Whole-Body Irradiation 1Thiotepa 1Tacrolimus 1Sugammadex 1Mycophenolic Acid 1Levetiracetam 1Dexamethasone 1Bortezomib 1Antilymphocyte Serum 1Alemtuzumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
beta-Thalassemia × fludarabine phosphate × Clear all
NCT01049854 2018-08-21

CD34+Selection for Partially Matched Family or Matched Unrelated Adult Donor Transplant

New York Medical College

Phase 2 Completed
20 enrolled
Classical hematologyLymphoidMyeloidOther hematologic neoplasm

Bone Marrow Failure Disorders, Anemia, Sickle Cell, Immunologic Deficiency Syndromes, Leukemia, Lymphoma, Metabolism, Inborn Errors, Histiocytosis, beta-Thalassemia

Data powered by HemOnc (CC BY 4.0) Colophon âš¡